Results from a phase 1 trial of lepodisiran, a short interfering RNA directed at hepatic synthesis of apolipoprotein(a), indicates use of the 608 mg formulation of the agent was associated with a 97% in lipoprotein(a) [Lp(a)]. Presented at the American Heart Association Scientific Sessions 2023 by Steve Nissen, MD, chief academic officer of the Heart Vascular & Thoracic Institute at Cleveland Clinic, results of the trial provide insight into the safety and efficacy of 6 dosages of lepodisiran relative to placebo therapy for lowering Lp(a) in adults without cardiovascular disease and with Lp(a) serum concentrations of 75 nmol/L or greater. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more